Archive

EHA 2018: Molecular profiling in multiple myeloma

Written by Karen Ramirez | 3 Aug 2018

In addition to clinical segmentation of MM patients as young or elderly and fit or frail, genetic factors convey important prognostic information and should be taken into account… read more.

Ezcema drug shows efficacy in moderate-to-severe uncontrolled asthma

Written by Karen Ramirez | 3 Aug 2018

Patients with moderate-to-severe uncontrolled asthma treated with the ezcema drug dupilumab have achieved significantly lower rates of severe asthma exacerbation than those using a placebo. Researchers reported this… read more.

EHA 2018: OPTIMISMM

Written by Karen Ramirez | 24 Jun 2018

Professor Paul Richardson (Boston, USA) presented the results of the OPTIMISMM study which compared the efficacy of pomalidomide, bortezomib and dexamethasone (PVd) with bortezombib and dexamethasone alone (Vd)… read more.

EHA 2018: Immunotherapy in MM: why, when and how?

Written by Karen Ramirez | 24 Jun 2018

The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.

EHA 2018: The Issue of Frailty in MM

Written by Karen Ramirez | 24 Jun 2018

When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.

EHA 2018: Preferred treatment combinations and sequencing in transplant eligible and elderly MM patients

Written by Karen Ramirez | 24 Jun 2018

The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.

BSH 2018: Hodgkin lymphoma: tackling treatment challenges in the older patient

Written by Christine Clark | 21 Jun 2018

Managing Hodgkin lymphoma in elderly patients can be challenging, given that trial data do not reflect the picture in elderly patients and performance status can vary widely. The… read more.

BSH 2018: Molecular biology to drive rational drug usage

Written by Christine Clark | 20 Jun 2018

Gene expression profiling has shown that that the activated B-cell and germinal centre B-cell subtypes of diffuse large B-cell lymphoma are driven by different oncogenic pathways and this may… read more.

BSH 2018 Highlights

Written by Karen Ramirez | 20 Jun 2018

In the video, Dr Cathy Burton (Leeds), Dr Stella Bowcock (London) and Dr Stephen Robinson (Bristol) give their highlights from this year’s BSH meeting, including the Lymphoma Specialist Interest Group (SIG) which held a… read more.

BSH 2018: Creating off-site, nurse-led treatment units for administration of chemotherapy to people with lymphoma

Written by Christine Clark | 20 Jun 2018

The launch of biosimilar rituximab provided an opportunity to save £300,000 per year but called for time-consuming intravenous administration that exceeded the capacity of the hospital unit. Off-site… read more.

Denmark: 1 in 4 people leave work a year after a heart attack

Written by Gary Finnegan | 11 May 2018

One in four people leave their job within a year of returning to work after having a heart attack, according to a study from Denmark in the Journal… read more.

BSH 2018: Debate: CAR-T cell therapy will become the standard of care for relapsed high-grade B-cell lymphoma within 5 years

Written by Christine Clark | 11 May 2018

Is CAR-T cell therapy a realistic treatment option for patients with large B cell lymphoma who otherwise have no curative options or an expensive new treatment that is… read more.

« Previous 1 … 3 4 5 6 7 … 44 Next »

Archive

Subscribe for our mailing list

Follow Us